Inhibition of tumor growth by blocking angiogenesis and Ras activity

The discovery and development of novel small molecule drugs to fight cancer is a challenging task. This book shows the whole path from the hit identification and hit-to-lead process to the preclinical studies required to validate therapeutic targets and to develop novel anticancer treatments that could potentially reach the clinic. Here two new series of compounds are described: a family of antiangiogenic compounds and a series of ICMT inhibitors that block Ras activity. These are two innovative examples of some of the most recent advances in the Medicinal Chemistry field in the search for novel effective treatments for cancer. A must-read for anyone who wants to learn the first steps of drug development as well as for any expert of the field who wants to stay current with the latest discoveries in the field of antitumor drugs.